Association Between Low-Molecular-Weight Heparin and Risk of Bleeding Among Hemodialysis Patients: A Retrospective Cohort Study

Hind H. Lazrak¹, Emilie René¹, Naoual Elftouh¹, and Jean-Philippe Lafrance¹,²,³

Abstract

Background: Low-molecular-weight heparins (LMWH) replaced unfractionated heparin (UFH) in multiple indications. Although LMWH efficacy in hemodialysis was demonstrated through multiple studies, their safety remains controversial. The potential bioaccumulation in patients undergoing chronic hemodialysis raised the question of bleeding risk among this population.

Objective: The aim of this study was to evaluate bleeding risk among patients with chronic hemodialysis receiving LMWH or UFH for the extracorporeal circuit anticoagulation.

Design: We conducted a retrospective cohort study on data extracted from the Régie de l’assurance maladie du Québec (RAMQ) and Med-Echo databases from January 2007 to March 2013.

Setting: Twenty-one hemodialysis centers in the province of Québec, Canada.

Patients: Chronic hemodialysis patients.

Measurements: Bleeding risk evaluated by proportional Cox model for time-dependent exposure using demographics, comorbidities, and drug use as covariates.

Methods: Minor, major, and total bleeding events identified using International Classification of Diseases, Ninth Revision (ICD-9)/International Classification of Diseases, Tenth Revision (ICD-10) codes in the RAMQ and Med-Echo databases. Exposure status to LMWH or UFH was collected through surveys at the facility level.

Results: We identified 5322 prevalent and incident patients with chronic hemodialysis. The incidence rate for minor, major, and total bleeding was 9.45 events/1000 patient-year (95% confidence interval [CI]: 7.61-11.03), 24.18 events/1000 patient-year (95% CI: 21.52-27.08), and 32.88 events/1000 patient-year (95% CI: 29.75-36.26), respectively. We found similar risks of minor adjusted hazard ratio (HR: 1.04; 95% CI: 0.68-1.61), major (HR: 0.83; 95% CI: 0.63-1.10), and total bleeding (HR: 0.90; 95% CI: 0.72-1.14) when comparing LMWH with UFH.

Limitations: Potential misclassification of patients’ exposure status and possible underestimation of minor bleeding risk.

Conclusion: LMWH was not associated with a higher minor, major, or total bleeding risk. LMWH did not increase the risk of bleeding compared with UFH for the extracorporeal circuit anticoagulation in hemodialysis. The convenience of use and predictable effect made LMWH a suitable alternative to UFH in hemodialysis.

Abrégé

Contexte: Les héparines de faible poids moléculaire (HFPM) ont remplacé les héparines non fractionnées (HNF) dans de multiples indications. Quoique l’efficacité des HFPM en hémodialyse ait été démontrée par un grand nombre d’études, leur innocuité demeure controversée; la possible bioaccumulation des HFPM chez les patients en hémodialyse chronique soulève le risque d’hémorragie au sein de cette population.

Objectif de l’étude: Cette étude visait à évaluer le risque d’hémorragie dans une cohorte de patients en hémodialyse chronique et traités par HFPM ou HNF comme anticoagulant pour le circuit extracorporel.

Type d’étude: Nous avons mené une étude de cohorte rétrospective sur les données de janvier 2007 à mars 2013, extraites des bases de données de la RAMQ et de Med-Echo.

Cadre: Les données proviennent de 21 centres d’hémodialyse de la province de Québec (Canada).

Sujets: Patients en hémodialyse chronique.
Mesures: Le risque d’hémorragie a été évalué par un modèle proportionnel de Cox pour l’exposition en fonction du temps et avec les covariables suivantes : données démographiques, comorbidités existantes et usage de médicaments.

Méthodologie: Les épisodes d’hémorragie mineure, majeure et totale ont été colligés à l’aide des codes de la CIM-9 et de la CIM-10 dans les bases de données de la RAMQ et de Med-Echo. Des sondages menés dans les établissements ont permis de déterminer l’exposition aux HFPM ou aux HNF.

Résultats: Nous avons retenu un total de 5 322 cas incidents et prévalents de patients en hémodialyse chronique pour l’étude. Les taux d’incidence pour les hémorragies mineures, majeures et totales étaient de 9,45 événements par 1 000 années-patients (IC 95 % : 7,61-11,03), de 24,18 événements par 1 000 années-patients (IC 95 % : 21,52-27,08) et de 32,88 événements par 1 000 années-patients (IC 95 % : 29,75-36,26) respectivement. Nous avons observé un risque comparable d’hémorragie mineure (rapport de risque corrigé : 1,04; IC 95 % : 0,68-1,61), majeure (rapport de risque corrigé : 0,83; IC 95 % : 0,63-1,10) et totale (rapport de risque corrigé : 0,90; IC 95 % : 0,72-1,14) lorsque nous avons comparé les HFPM aux HNF.

Limites: Nos résultats sont limités par les probables erreurs dans le classement de l’exposition des patients aux héparines, de même que par une possible sous-évaluation des risques d’hémorragies mineures.

Conclusion: Les HFPM n’ont pas été associées à un risque accru d’hémorragies mineures, majeures ou totales. De plus, lorsqu’elles ont été utilisées comme anticoagulant du circuit extracorporel en hémodialyse, les HFPM n’ont pas augmenté le risque d’hémorragie par rapport aux HNF. Ainsi, la commodité d’utilisation et l’effet prévisible des HFPM en font une solution de remplacement adéquate aux HNF en hémodialyse.

Keywords
heparin, low-molecular-weight, unfractionated heparin, hemorrhage, kidney failure, chronic, pharmacoepidemiology

Received January 31, 2018. Accepted for publication June 18, 2018.
almost half of hemodialysis units made the choice to replace UFH by one of the available LMWH, therefore offering a unique opportunity to study this safety issue and providing strong evidence to physicians and decision makers.

The aim of this study was to evaluate the association between the use of LMWH in a context of extracorporeal anticoagulation, compared with UFH, and the risk of bleeding in a cohort of chronic hemodialysis patients.

Methods

Study Population and Data Sources

We conducted a retrospective cohort study to assess the association of the extracorporeal circuit anticoagulation with LMWH, compared with UFH, and bleeding risk among prevalent and incident chronic hemodialysis patients. Study data were obtained from the Régie de l’assurance maladie du Québec (RAMQ). This provincial single-payer health insurance plan provided to all residents of the Province of Québec, Canada, covers medical and hospital services. Information on all medical visits, diagnostic codes (using International Classification of Diseases [ICD]), medical procedures during in-patient and out-patient encounters, and hospital discharge summaries (Med-Echo) are provided by this administrative database. The Med-Echo database provides details on the date of admission and discharge, primary and secondary diagnoses, and the procedures performed during the hospital stay. Moreover, all individuals aged 65 years and older, individuals on welfare, and workers not insured by a private insurance company are covered by the provincial drug plan. Exposure to heparin is not recorded in the RAMQ drug plan and was collected at each of the 21 participating hemodialysis units in the province of Québec. The list of participating centers is provided in the supplementary appendix.

Study Cohort

We built a cohort of both prevalent and incident adult patients on maintenance hemodialysis between January 1, 2007, and March 31, 2013, identified in the RAMQ database. To be included, patients could not have a prior kidney transplant and should have at least 90 days of follow-up after hemodialysis initiation. Prevalent patients could not have started dialysis before January 1, 2001, to allow us to calculate vintage years (how many years they received chronic hemodialysis prior to cohort entry). The first hemodialysis code respecting the inclusion criteria was defined as the index date. End of follow-up corresponded to the date of kidney transplant, switch to peritoneal dialysis, end of study, or death, whichever occurred first. Moreover, only patients who received hemodialysis in one of our participating centers were kept. Patients followed in a participating center that did not provide exposure status or with an unclear exposure status were excluded.

Exposure Definition

The use of heparin as an extracorporeal anticoagulant during hemodialysis is defined at the center level. Each center has its own anticoagulation protocol and heparin is administered in hospital at every session. Therefore, exposure status could not be retrieved through the RAMQ drug coverage plan. The type of heparin used (tinzaparin, dalteparin, enoxaparin, nadroparin, UFH) was collected at the center level between January 1, 2007, and March 31, 2013. We recorded any changes in their respective protocols, including all changes of heparin type through the study period. Centers could have more than one heparin exposure period during the study time frame; however, transition periods from one heparin to another were removed from the analysis, as we could not segregate which form of heparin each patient received. Patients’ exposure status depended on the center where and when they were receiving hemodialysis. The exposure status for each patient changes every time: (1) the unit changes the protocol for a different heparin; and (2) the patient receives 2 or more hemodialysis sessions in a different unit.

Outcome Definition

All admissions for bleeding as a primary diagnosis on the discharge sheet during the study period were identified through the International Classification of Diseases, Ninth Revision (ICD-9) and International Classification of Diseases, Tenth Revision (ICD-10) codes (see Supplementary appendix for list of codes and their definition). Only the first bleeding event that occurs during the patient’s follow-up time was kept and was categorized as being a minor or a major bleeding.

Covariates

Covariates were evaluated at baseline through the RAMQ and Med-Echo and included age, gender, follow-up time, vintage time (time undergoing chronic hemodialysis for prevalent patients), cohort entry year, hospitalization in prior year, comorbidities, and drug use in the 6 months prior to cohort entry (see Table 1 for more details).

Statistical Analysis

Mean and standard deviation (SD) or median and interquartile range (IQR) were used to present descriptive baseline data where appropriate. Comorbidities are presented as a frequency expressed as a proportion (%).

Outcomes’ incidence rates were calculated by dividing the number of events (total bleeding, major bleeding, or minor bleeding) by the total patient-years (p-y) of follow-up and are presented as incidence rate per 1000 p-y. And 95% confidence intervals (CI) for rates were calculated using a Poisson distribution (inversed gamma formula).
The hazard ratio (HR) for the first event of each outcome was estimated using a time-dependent Cox proportional hazard model. It was adjusted for all the comorbidities presented in Table 1. All analyses were done using SAS 9.4 (Cary, North Carolina).

Sensitivity Analysis

LMWH are not interchangeable and should also be analyzed separately. We conducted the analyses using the same method but separating tinzaparin periods from dalteparin with UFH as the reference group. Moreover, bleeding risk was also evaluated by keeping only incident patients in the cohort.

Ethical Considerations

This study was approved by the Government of Québec ethics committee (Commission d'accès à l'information) and all hospitals ethics committees. Informed consent was waived.

Results

Our cohort included 5322 prevalent and incident patients on maintenance hemodialysis in one of the participating centers with at least one period with a known heparin exposure status, and represented 6079 patients when first exposed to UFH and LMWH (some patients were switched from one form of heparin to the other during the study period). Cumulative follow-up time under UFH was 7493 p-y, 3832 p-y for tinzaparin, and 189 p-y for dalteparin. Most patients (86%) were exposed to one type of heparin only, 12% switched once from one heparin to another, and the remaining (2%) switched more than once meaning that they switched back to their prior exposure.

Incident patients represented 70.6% of the cohort. Prevalent patients had a mean of 0.6 ± 1.3 vintage years at cohort entry. Mean age was 66.4 ± 14.0 years at cohort entry and 39.3% were women. Median follow-up time was 2.0 years (IQR: 0.8-3.6). Patients’ characteristics were overall similar between exposure groups (Table 1). However, in the LMWH exposed group, there were more incident patients, less hospitalizations in the prior year, and less prior bleeding.

Table 1. Patients’ Characteristics at First Exposure to LMWH and UFH.

| Variable                                           | All       | LMWH     | UFH       |
|----------------------------------------------------|-----------|----------|-----------|
|                                                   | N = 6079  | n = 2292 | n = 3787  |
| Baseline                                           |           |          |           |
| Age (years ± SD)                                   | 66.4 ± 14.0 | 67.1 ± 13.6 | 65.9 ± 14.2 |
| Sex (female)                                       | 2392      | 917      | 1475      |
| Follow-up (median and IQR)                        | 2.0 (0.8-3.6) | 2.3 (1.1-4.1) | 2.1 (0.9-3.8) |
| Incident patient                                   | 4289      | 1741     | 2548      |
| Vintage (years ± SD)                               | 0.6 ± 1.3 | 0.5 ± 1.2 | 0.7 ± 1.4 |
| Hospitalization in prior year                      | 3954      | 1405     | 2549      |
| Comorbidities                                      |           |          |           |
| Cardiovascular disease                             | 2813      | 1003     | 1810      |
| Cerebrovascular disease                            | 414       | 143      | 271       |
| Chronic pulmonary disease                          | 1133      | 415      | 718       |
| Cirrhosis or chronic liver disease                 | 287       | 99       | 188       |
| Congestive heart failure                           | 1675      | 639      | 1036      |
| Congestive heart failure                           | 3163      | 1209     | 1954      |
| Hyperlipidemia                                     | 3703      | 1370     | 2333      |
| Hypertension                                       | 4315      | 1626     | 2689      |
| Malignancy                                         | 1065      | 389      | 676       |
| Peripheral vascular disease                        | 1455      | 541      | 914       |
| Peptic ulcer, GERD, reflux disease                 | 692       | 231      | 461       |
| Prior bleeding                                     | 331       | 96       | 235       |
| Drug use                                           |           |          |           |
| Oral anticoagulants                                | 814       | 277      | 537       |
| Antiplatelet aggregation drug                      | 708       | 267      | 441       |
| Erythropoietin stimulating agents                  | 3174      | 1138     | 2036      |
| Proton pump inhibitors                             | 2410      | 869      | 1541      |
| NSAID                                              | 2989      | 1130     | 1859      |
| Steroids                                           | 779       | 254      | 525       |

Note. LMWH = low-molecular-weight heparin; UFH = unfractionated heparin; IQR = interquartile range; GERD = gastroesophageal reflux disease; NSAID = nonsteroidal anti-inflammatory drugs.

*At cohort entry.
A total of 403 bleeding events were identified from 12,255.41 p-y. The incident rate for total bleeding was 32.9 events/1000 p-y (95% CI: 29.75-36.26). The major bleeding and minor bleeding incidence rates were respectively 24.2 events/1000 p-y (95% CI: 21.52-27.08), with 300 events per 12,405.83 p-y, and 9.5 events/1000 p-y (95% CI: 7.61-11.03) with 117 minor events identified among 12,714.00 p-y. The two most frequent major bleeding codes were gastrointestinal hemorrhage and vitreous hemorrhage. For minor bleeding, the most frequent codes were hemorrhage and hematoma complicating a procedure as well as hemorrhage of anus and rectum. The total bleeding risk was similar (HR: 0.90; 95% CI: 0.72-1.14) for LMWH compared with UFH. An increased total bleeding risk of 36% for diabetes (HR: 1.36; 95% CI: 1.07-1.72) and 37% for malignancy (HR: 1.37; 95% CI: 1.05-1.77) was observed. Compared with UFH, the risk of major bleeding when using LMWH was comparable (HR: 0.83; 95% CI: 0.63-1.08) with diabetes increasing bleeding risk by 45% (HR: 1.45; 95% CI: 1.10-1.91). Minor bleeding risk did not increase with LMWH in comparison with UFH (HR: 1.04; 95% CI: 0.68-1.62). Malignancy and oral anticoagulants were statistically significant with an increased minor bleeding risk of 128% (HR: 2.28; 95% CI: 1.48-3.52) and 75% (HR: 1.75; 95% CI: 1.04-2.94), respectively. The complete results are presented in Tables 2, 3, and 4.

### Sensitivity Analysis

Bleeding risk was also evaluated by type of LMWH using UFH as the reference. From the total LMWH follow-up time, tinzaparin accounted for 95% of the time and the remaining 5% was under dalteparin (189 p-y). For both tinzaparin and dalteparin, when compared with UFH, there was no statistical difference for total and major bleeding. The total bleeding risk with tinzaparin was similar to UFH (HR: 0.96; 95% CI: 1.48-3.52) and 75% (HR: 1.75; 95% CI: 1.04-2.94), respectively. The complete results are presented in Tables 2, 3, and 4.

### Table 2. Total Bleeding Hazard Ratio for LMWH Compared With UFH.

| Parameter | Unadjusted HR | Adjusted HR |
|-----------|---------------|-------------|
|           | HR            | 95% CI      | HR            | 95% CI        |
| Heparin exposure |                |             |               |               |
| LMWH vs UFH | 0.88          | 0.70-1.11   | 0.90          | 0.72-1.14     |
| Baseline |                |             |               |               |
| Age        | 1.00          | 1.00-1.01   | 1.00          | 0.99-1.01     |
| Sex (female) | 1.07          | 0.86-1.32   | 1.11          | 0.89-1.38     |
| Incident patient | 1.24          | 0.97-1.58   | 0.79          | 0.61-1.03     |
| Hospitalization in prior year | 1.41          | 1.12-1.78   | 1.13          | 0.88-1.47     |
| Comorbidities |                |             |               |               |
| Cardiovascular disease | 1.36          | 1.10-1.68   | 1.15          | 0.89-1.49     |
| Cerebrovascular disease | 1.31          | 0.91-1.90   | 1.07          | 0.72-1.59     |
| Chronic pulmonary disease | 1.31          | 1.02-1.70   | 1.07          | 0.81-1.41     |
| Cirrhosis or chronic liver disease | 1.58          | 1.03-1.64   | 1.35          | 0.87-2.11     |
| Congestive heart failure | 1.31          | 1.04-1.64   | 1.01          | 0.78-1.31     |
| Diabetes | 1.49          | 1.20-1.86   | 1.36          | 1.07-1.72     |
| Hyperlipidemia | 1.01          | 0.81-1.26   | 0.90          | 0.69-1.18     |
| Hypertension | 1.33          | 1.03-1.71   | 1.01          | 0.75-1.35     |
| Malignancy | 1.41          | 1.09-1.82   | 1.37          | 1.05-1.77     |
| Peripheral vascular disease | 1.33          | 1.06-1.68   | 1.14          | 0.88-1.48     |
| Peptic ulcer, GERD, reflux disease | 1.53          | 1.15-2.04   | 1.25          | 0.90-1.72     |
| Prior bleeding | 1.68          | 1.14-2.48   | 1.35          | 0.88-2.05     |
| Drug use |                |             |               |               |
| Oral anticoagulants | 1.37          | 1.03-1.81   | 1.31          | 0.98-1.77     |
| Antiplatelet aggregation drug | 0.93          | 0.67-1.30   | 0.88          | 0.61-1.25     |
| Erythropoietin stimulating agents | 0.97          | 0.78-1.20   | 1.00          | 0.77-1.30     |
| Proton pump inhibitors | 0.99          | 0.80-1.23   | 0.87          | 0.68-1.11     |
| NSAID | 1.01          | 0.81-1.24   | 1.00          | 0.77-1.29     |
| Steroids | 1.09          | 0.79-1.50   | 1.07          | 0.77-1.47     |

Note. LMWH = low-molecular-weight heparin; UFH = unfractionated heparin; HR = hazard ratio; CI = confidence interval; GERD = gastroesophageal reflux disease; NSAID = nonsteroidal anti-inflammatory drugs.

aAt cohort entry.
statistically significant compared with UFH for the same outcome (HR: 1.12; 95% CI: 0.71-1.76). Confidence intervals were larger for dalteparin because of a shorter exposure time.

When only incident patients were included in the cohort, there was no difference in total (HR: 0.85; 95% CI: 0.64-1.13), major (HR: 0.78; 95% CI: 0.55-1.09), and minor (HR: 1.03; 95% CI: 0.61-1.72) bleeding risk.

Discussion

The controversy around LMWH’s bleeding risk in hemodialysis has been lingering despite several published clinical trials attempting to answer this question. In this retrospective cohort study, we tackle the problematic of total bleeding, major bleeding, and minor bleeding associated with LMWH as a group and individually for in-hospital hemodialysis anticoagulation.

Regardless of the bleeding category we looked at, LMWH showed to be as safe as UFH for bleeding risk. Major bleeding accounts for most of all observed bleeding events. The most likely explanation is that we had only access to hospitalization data and even if we had an exhaustive list of both minor and major bleeding codes, it is less likely to have a hospitalization triggered by a minor bleeding. It would be reasonable to think that due to their nature, in our study’s context, minor bleedings would be underestimated. However, we are confident that major bleedings were adequately captured. Among hemodialysis patients, bleeding incidence rates published previously varied highly based on the study’s context and the type of bleeding considered as the outcome. Holden et al reported an incidence rate for major bleeding of 2.5 events/100 p-y and could range from 3.1 to 6.3 events/100 p-y depending on patients’ use of aspirin and/or warfarin. Another study evaluating the incidence of moderate to severe bleeding events among nondialysis patients receiving therapeutic doses of UFH and LMWH estimated the rate to 3.5 events/100 p-y. We estimated a major bleeding incidence rate of 2.42 events/100 p-y, which is in the lower range of what was previously published.

Table 3. Major Bleeding Hazard Ratio for LMWH Compared With UFH.

| Parameter | Unadjusted HR | Adjusted HR |
|-----------|---------------|-------------|
|           | HR 95% CI     | HR 95% CI   |
| Heparin exposure |                |             |
| LMWH vs UFH     | 0.82 0.63-1.08 | 0.83 0.63-1.10 |
| Baseline |                |             |
| Age^a   | 1.00 0.99-1.01 | 1.00 0.99-1.01 |
| Sex (female) | 1.07 0.84-1.37 | 1.11 0.87-1.43 |
| Incident patient | 1.18 0.90-1.56 | 0.84 0.62-1.13 |
| Hospitalization in prior year | 1.24 0.96-1.61 | 0.99 0.74-1.33 |
| Comorbiditie |                |             |
| Cardiovascular disease | 1.44 1.13-1.84 | 1.30 0.97-1.73 |
| Cerebrovascular disease | 1.52 1.02-2.27 | 1.31 0.85-2.00 |
| Chronic pulmonary disease | 1.14 0.84-1.55 | 0.96 0.69-1.34 |
| Cirrhosis or chronic liver disease | 1.65 1.02-2.67 | 1.42 0.87-2.33 |
| Congestive heart failure | 1.24 0.96-1.62 | 0.98 0.73-1.33 |
| Diabetes | 1.60 1.24-2.05 | 1.45 1.10-1.91 |
| Hyperlipidemia | 1.03 0.80-1.33 | 0.93 0.69-1.27 |
| Hypertension | 1.31 0.98-1.74 | 1.02 0.74-1.42 |
| Malignancy | 1.15 0.84-1.57 | 1.14 0.83-1.57 |
| Peripheral vascular disease | 1.26 0.96-1.65 | 1.03 0.76-1.40 |
| Peptic ulcer, GERD, reflux disease | 1.56 1.12-2.16 | 1.30 0.90-1.87 |
| Prior bleeding | 1.62 1.03-2.52 | 1.29 0.80-2.09 |
| Drug use |                |             |
| Oral anticoagulants | 1.12 0.79-1.57 | 1.07 0.75-1.54 |
| Antiplatelet aggregation drug | 0.95 0.66-1.39 | 0.87 0.58-1.30 |
| Erythropoietin stimulating agents | 0.94 0.73-1.21 | 1.00 0.74-1.34 |
| Proton pump inhibitors | 0.98 0.76-1.25 | 0.89 0.67-1.17 |
| NSAID | 1.02 0.80-1.30 | 0.99 0.74-1.32 |
| Steroids | 0.93 0.63-1.37 | 0.95 0.64-1.42 |

Note. LMWH = low-molecular-weight heparin; UFH = unfractionated heparin; HR = hazard ratio; CI = confidence interval; GERD = gastroesophageal reflux disease; NSAID = nonsteroidal anti-inflammatory drugs.

^aAt cohort entry.
Results were similar when comparing separately tinzaparin and dalteparin with UFH. Tinzaparin proved to be as safe as UFH for total, major, and minor bleeding. No minor bleeding events were recorded with dalteparin making it impossible to evaluate the risk of minor bleeding. However, dalteparin appears as safe as UFH for major and total bleeding risk. Tinzaparin did not represent a higher bleeding risk compared with UFH in hemodialysis. Dalteparin did not seem to present a higher bleeding risk either but we had fewer data compared with UFH and tinzaparin with a shorter follow-up time.

As LMWH were introduced as a potential replacement to UFH for extracorporeal circuit anticoagulation in hemodialysis, numerous studies were conducted and published looking at their efficacy and safety. Although efficacy was thoroughly covered and demonstrated, LMWH safety status remained unclear. Bioaccumulation risk was always a concern with LMWH with the assumption that they are exclusively eliminated by the kidneys, which is problematic in patients undergoing hemodialysis. Multiple studies were published measuring the possible bioaccumulation of different types of LMWH. The results were as different as LMWH’s pharmacokinetic profiles differ from each other. Bioaccumulation studies were conflicting; some showed an accumulation of dalteparin in patients with severe renal failure, while there was no bioaccumulation in other studies in the same population. Tinzaparin was also evaluated and was not found to accumulate with severe renal failure. A study published by Johansen and Balchen highlighted the fact that not all LMWH were exclusively eliminated by kidneys and some could be eliminated by the liver when their molecular weight was higher, and therefore would not accumulate in patients in hemodialysis. Tinzaparin is the heavier form of LMWH. A recent single center observational study evaluated the risk of major bleeding in hemodialysis comparing LMWH with UFH and found no difference between both groups. These findings were consistent with our own results.

Diabetes was a statistically significant risk factor for both major and total bleeding. In other studies, diabetes was

| Parameter                                      | Unadjusted HR | Adjusted HR |
|------------------------------------------------|---------------|-------------|
|                                                | HR            | 95% CI      | HR            | 95% CI      |
| Heparin exposure                               |               |             |               |             |
| LMWH vs UFH                                    | 0.96          | 0.62-1.48   | 1.04          | 0.68-1.61   |
| Baseline                                       |               |             |               |             |
| Age                                            | 1.01          | 0.99-1.03   | 1.01          | 0.99-1.03   |
| Sex (female)                                   | 1.08          | 0.72-1.61   | 1.12          | 0.75-1.67   |
| Incident patient                               | 1.19          | 0.75-1.88   | 0.80          | 0.48-1.33   |
| Hospitalization in prior year                  | 2.19          | 1.34-3.59   | 1.71          | 0.98-3.00   |
| Comorbidities                                  |               |             |               |             |
| Cardiovascular disease                         | 1.16          | 0.78-1.72   | 0.83          | 0.52-1.32   |
| Cerebrovascular disease                        | 0.57          | 0.21-1.54   | 0.41          | 0.15-1.13   |
| Chronic pulmonary disease                      | 2.03          | 1.31-3.13   | 1.55          | 0.95-2.51   |
| Cirrhosis or chronic liver disease             | 1.17          | 0.47-2.89   | 0.95          | 0.38-2.42   |
| Congestive heart failure                       | 1.54          | 1.02-2.34   | 1.20          | 0.73-1.97   |
| Diabetes                                       | 1.34          | 0.89-2.01   | 1.28          | 0.82-2.00   |
| Hyperlipidemia                                 | 0.82          | 0.55-1.22   | 0.66          | 0.41-1.08   |
| Hypertension                                   | 1.60          | 0.97-2.64   | 1.07          | 0.60-1.91   |
| Malignancy                                     | 2.58          | 1.70-3.92   | 2.28          | 1.48-3.52   |
| Peripheral vascular disease                    | 1.41          | 0.92-2.16   | 1.32          | 0.82-2.12   |
| Peptic ulcer, GERD, reflux disease             | 1.42          | 0.82-2.46   | 1.11          | 0.62-2.00   |
| Prior bleeding                                 | 1.86          | 0.93-3.71   | 1.51          | 0.75-3.07   |
| Drug use                                       |               |             |               |             |
| Oral anticoagulants                            | 1.84          | 1.13-2.97   | 1.75          | 1.04-2.94   |
| Antiplatelet aggregation drug                  | 0.74          | 0.37-1.46   | 0.79          | 0.38-1.66   |
| Erythropoietin stimulating agents              | 1.07          | 0.72-1.59   | 1.08          | 0.67-1.76   |
| Proton pump inhibitors                         | 0.96          | 0.64-1.45   | 0.78          | 0.49-1.24   |
| NSAID                                          | 1.00          | 0.67-1.48   | 1.15          | 0.74-1.79   |
| Steroids                                       | 1.58          | 0.94-2.68   | 1.36          | 0.78-2.37   |

Note. LMWH = low-molecular-weight heparin; UFH = unfractionated heparin; HR = hazard ratio; CI = confidence interval; GERD = gastroesophageal reflux disease; NSAID = nonsteroidal anti-inflammatory drugs. At cohort entry.
identified as an independent risk factor for major bleeding events.\textsuperscript{1,18} Malignancy was also identified in our study as a factor increasing the risk of minor and total bleeding. In a study comparing bleeding risk in patients receiving anticoagulants with or without cancer, the former group had a higher risk of bleeding.\textsuperscript{19} The more advanced cancer’s stage is, the higher the risk of hemorrhage.\textsuperscript{20} As for the increased risk of minor bleeding with oral anticoagulant, there is no clear answer in previously published studies.\textsuperscript{21} A study published by Limdi et al\textsuperscript{22} and evaluating complications with warfarin by kidney function stage showed an increased risk of first bleeding event (HR: 2.33; 95% CI: 1.44-3.75) in patients with an estimated glomerular filtration rate lower than 30 mL/min/1.73 kg/m\textsuperscript{2}.

As expected, the proportion of patients by year of cohort entry slightly decreased through time for UFH whereas it went in the opposite direction for LMWH. The later started being used in hemodialysis units in 2007 and the number of units switching from UFH kept on increasing year after year leading to more patients, therefore more exposure time, receiving LMWH.

Our study was the first multicenter cohort study evaluating minor, major, and total bleeding risk with LMWH for the extracorporeal circuit anticoagulation in hemodialysis on a large scale with a long follow-up. The use of administrative data from our provincial health care insurance allowed including all eligible patients undergoing hemodialysis in participating centers and linking all the available patients’ information to our collected exposure data at the center level. The universal health care insurance provided in the province of Québec offers systematic care to dialysis patients limiting selection bias. The use of RAMQ and Med-echo data allowed us to collect multiple covariates including drug exposure and therefore minimizing confounding. By defining our exposure as being time-dependent and allowing patients to switch exposure during their follow-up, we avoided the introduction of an immortal time bias.

Our study has some limitations. The exposure was measured at the center level, meaning we cannot be certain that all patients receiving hemodialysis in these units were on the regular anticoagulation protocol. There was a potential misclassification bias for exposure status; however, the risk would be similar for both UFH and LMWH. Also, we could not adjust based on individual doses since that information was not available. Moreover, identification of bleeding events could not be done by chart reviews because of the multicenter nature of our study. We had to rely on ICD codes reported on hospital discharge sheets. Since only events leading to hospitalization could be identified, we most likely could not capture all minor bleeding events. Although we had access to many covariables to introduce them in the model, confounding remains possible. Finally, only a limited number of follow-up time were under dalteparin, which made the bleeding risk estimation for this form of LMWH less reliable.

In conclusion, our large retrospective cohort study showed that LMWH, more specifically tinzaparin, is as safe as UFH for minor, major, and total bleeding risk when used for the extracorporeal circuit anticoagulation in hemodialysis. With LMWH replacing UFH for multiple indications and their convenient use, practitioners and policy makers needed a clear evidence of their safety since efficacy was already proven. Ongoing clinical randomized studies, like Use of Tinzaparin for Anticoagulation in Hemodialysis (HEMOTIN) trial, are comparing specific forms of LMWH to UFH in hemodialysis. Results from those studies will add to the body of evidence and, combined to our study, will offer a better understanding of bleeding risk associated with LMWH. Multiple studies demonstrated that when considering the product’s cost, material and nursing time, the cost of both forms of heparins was similar. Tinzaparin is a safe and simple alternative to UFH in hemodialysis. Heparin is known to cause other side effects and whether LMWH has the same impact is still a pending question.

**Ethics Approval and Consent to Participate**

This study was approved by the Government of Québec ethics committee (Commission d’accès à l’information) and all hospitals ethics committees. Informed consent was waived.

**Consent for Publication**

Not applicable.

**Availability of Data and Materials**

The datasets cannot be made available due to privacy restrictions of the Commission d’accès à l’information du Québec.

**Acknowledgments**

We would like to thank all our collaborators in the participating centers who made exposure data collection, and this study, possible in their respective hemodialysis units: Dr Pierre Cartier, Dr Karine Tousignant, Dr Carole Pichette, Dr Gérard Désaulniers, Dr Jean Proulx, Dr Sacha Deserres, Dr Paul Montambault, Dr Jean-François Cailhier, Dr George Soltys, Dr Damien Bélisle, Dr Marc Ghannoun, Dr Jean-Philippe Rioux, Dr Sylvain Brunet, Dr Marie-Josée Dion, Dr Paul Barré, and Dr Simon Desmeules.

**Declaration of Conflicting Interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**References**

1. Gould MK, Dembitzer AD, Doyle RL, et al. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. *Ann Intern Med.* 1999;130:800-809.
2. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. *Lancet*. 2000;355:1936-1942. doi:10.1016/S0140-6736(00)02324-2.

3. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. *Chest*. 2001;119:64S-94S.

4. Cronin RE, Reilly RF. Unfractionated heparin for hemodialysis: still the best option. *Semin Dial*. 2010;23:510-515. doi:10.1111/j.1525-139X.2010.00770.x.

5. Davenport A. The rationale for the use of low molecular weight heparin for hemodialysis treatments. *Hemodial Int*. 2013;17(suppl 1):S28-S32. doi:10.1111/hdi.12086.

6. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporal system. *Nephrol Dial Transplant*. 2002;17(suppl 7):63-71.

7. Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. *J Thromb Haemost*. 2009;7:1629-1632. doi:10.1111/j.1538-7836.2009.03556.x.

8. Cook D, Douketis J, Meade M, et al. Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. *Crit Care*. 2008;12:R32. doi:10.1186/cc6810.

9. Douketis J, Cook D, Meade M, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. *Arch Intern Med*. 2008;168:1805-1812. doi:10.1001/archinte.168.16.1805.

10. Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A. No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. *J Thromb Haemost*. 2011;9:1966-1972. doi:10.1111/j.1538-7836.2011.04458.x.

11. Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? *Exp Hematol Oncol*. 2013;2:21. doi:10.1186/2162-3619.

12. Lim W, Cook DJ,Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. *J Am Soc Nephrol*. 2004;15:3192-3206. doi:10.1097/01.ASN.0000145014.80714.35.

13. Holden RM, Harman GJ, Wang M, Holland D, Day AG. Major bleeding in hemodialysis patients. *Clin J Am Soc Nephrol*. 2008;3:105-110. doi:10.2215/CJN.01810407.

14. Cossette B, Pelletier ME, Carrier N, et al. Evaluation of bleeding risk in patients exposed to therapeutic unfractionated or low-molecular-weight heparin: a cohort study in the context of a quality improvement initiative. *Ann Pharmacother*. 2010;44:994-1002. doi:10.1345/aph.1M615.

15. Gouin-Thibault I, Pautas E, Siguret V. Safety profile of different low-molecular weight heparins used at therapeutic dose. *Drug Saf*. 2005;28:333-349.

16. Nadarajah L, Fan S, Forbes S, Ashman N. Major bleeding in hemodialysis patients using unfractionated or low molecular weight heparin: a single-center study. *Clin Nephrol*. 2015;84:274-279. doi:10.5414/CN108624.

17. De Berardis G, Lucisano G, D’Ettorre A, et al. Association of aspirin use with major bleeding in patients with and without diabetes. *JAMA*. 2012;307:2286-2294. doi:10.1001/jama.2012.5034.

18. Peng YL, Leu HB, Luo JC, et al. Diabetes is an independent risk factor for peptic ulcer bleeding: a nationwide population-based cohort study. *J Gastroenterol Hepatol*. 2013;28:1295-1299. doi:10.1111/jgh.12190.

19. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. *Blood*. 2002;100:3484-3488. doi:10.1182/blood-2002.

20. Pereira J, Phan T. Management of bleeding in patients with advanced cancer. *Oncologist*. 2004;9:561-570. doi:10.1634/theoncologist.9-5.

21. Basra SS, Tsai P, Lakkis NM. Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease. *J Am Coll Cardiol*. 2011;58:2263-2269. doi:10.1016/j.jacc.2011.08.051.

22. Limdi NA, Beasley TM, Baird MF, et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. *J Am Soc Nephrol*. 2009;20:912-921. doi:10.1681/ASN.2008070802.